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Abstract 
Background: Uric acid (UA) is known to exert neuroprotective effects in the brain. However, the mechanism of UA 
regulation in the brain is not well characterized. In our previous study, we described that the mouse urate transporter 
URAT1 is localized to the cilia and apical surface of ventricular ependymal cells. To further strengthen the hypothesis 
that UA is transported transcellularly at the ependymal cells, we aimed to assess the distribution of other UA trans-
porters in the murine brain.
Methods: Immunostaining and highly-sensitive in situ hybridization was used to assess the distribution of UA trans-
porters: GLUT9/URATv1, ABCG2, and URAT1.
Results: Immunostaining for GLUT9 was observed in ependymal cells, neurons, and brain capillaries. Immunostain-
ing for ABCG2 was observed in the choroid plexus epithelium and brain capillaries, but not in ependymal cells. These 
results were validated by in situ hybridization.
Conclusions: We propose that given their specific expression patterns in ependymal, choroid plexus epithelial, and 
brain capillary endothelial cells in this study, UA may be transported by these UA transporters in the murine brain. This 
may provide a novel strategy for targeted neuroprotection.
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Uric acid (UA) exerts a neuroprotective effect due to its 
antioxidant property, and epidemiological and experi-
mental evidence suggests that UA plays an important role 
in the development or progression of neurodegenerative 
disorders [1]. For instance, higher serum UA is associ-
ated with the decreased incidence and slower progres-
sion of Parkinson’s disease (PD) [2]. Moreover, recent 
studies indicate that UA transporter genes, which control 
the transport of UA in the kidney and extra renal tissues, 
and thus affect serum UA levels, are also associated with 
the risk and age at onset of PD [3–6]. In rodent models 
of PD, elevated UA levels attenuated behavioral and neu-
rodegenerative deficits [7, 8]. Urate-elevating clinical 
trials are currently underway in patients with the early 
stages of PD. An oral administration of inosine, a precur-
sor of UA, can elevate UA levels in serum and cerebro-
spinal fluid (CSF), with a persistent elevation of plasma 
antioxidant capacity [9, 10]. Further, CSF UA is inversely 
correlated with the clinical progression of PD, albeit to a 
lesser extent than serum UA [11]. However, the molec-
ular mechanism as to how the UA in blood reaches the 
brain parenchyma and affects neuronal viability remains 
unclear.
We previously demonstrated that URAT1, which is a urate 
transporter responsible for urate reabsorption in the kidney 
[12], is localized to cilia and the apical surface of ventricular 
ependymal cells in the murine brain [13]. Ependymal cells 
form a single-layer of epithelial cells which line the surface 
of the cerebral ventricles. Although the lateral ventricular 
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CSF-brain interface does not usually act as a barrier due to 
the lack of tight junctions and may allow passive molecu-
lar exchange, immunoreactivity of tight junction proteins 
has been demonstrated in the ependymal cells of specific 
regions of the third and fourth ventricles [14–17]. Therefore, 
alternative carrier-mediated transport systems may exist at 
the ependymal layer in addition to slow paracellular diffu-
sion. For example, a recent study indicates that the gluta-
mate transporter EAAT1, which is localized on the apical 
membrane of the ependymal cell is involved in the removal 
of l-Glutamate from the CSF [18]. It is also known that 
proximal tubules which express functional UA transporters, 
are leaky epithelial cells [19]. In this regard, we hypothesized 
that ependymal URAT1 and other transporters may func-
tion as a UA transporter between the ventricular CSF and 
the interstitial fluid of the brain parenchyma.
To further strengthen the hypothesis that UA trans-
port systems exist in ependymal cells, the aim of this 
study was to address if other UA transporters were also 
localized in those cells. In this study, we focused on two 
other UA transporters, GLUT9/URATv1 and ABCG2, 
which are known to regulate serum UA levels [20]. RT-
PCR analyses showed that mRNA encoding the long iso-
form of GLUT9 is found both in the human and murine 
brain [21, 22]. Furthermore, GLUT9 is also expressed in 
cultured dopaminergic neurones and astroglial cells [23]. 
However, the spatial distribution of GLUT9 in the brain 
is still unknown. Further, while ABCG2 luminal localiza-
tion in brain capillaries, and on murine choroid plexus 
epithelial cells has been previously described [24, 25], its 
localization on ependymal cells is still unknown.
Thus, the aim of this study was to investigate the dis-
tribution of GLUT9 and ABCG2 in the murine brain, 
particularly in ependymal cells. To do this, we performed 
immunostaining and highly-sensitive in  situ hybridiza-
tion analyses of the murine brain.
Methods
Animals
A total of seven male C57BL/6J mice (Sankyo Laborato-
ries, Tokyo, Japan), a male Abcg2-knockout (KO) mouse 
(FVB.129P2-Abcg2, Taconic Farms, Hudson, NY), and a 
littermate wild-type (WT) mouse were used in this study. 
Mice were maintained in 12 h light and dark cycles, with 
free access to food and water. All animal experiments 
were carried out in accordance with the guidelines for 
animal experimentation in Teikyo University and the 
University of Tokyo, and the project was approved by the 
local committee.
Tissue section preparation
To prepare fixed, frozen sections, mice were anesthe-
tized by pentobarbital injection (50  mg/kg, i.p.) and 
perfused intracardially with HEPES buffer (30  mM 
HEPES, 100  mM NaCl, 2  mM CaCl2, pH 7.4), followed 
by 4% paraformaldehyde (PFA) in HEPES buffer. Brains 
were then removed and post-fixed for 3 h at 4  °C in the 
same fixative. The post-fixed brains were cut coronally 
and cryoprotected in 15% sucrose (wt/vol) in PBS for 
48  h at 4  °C, embedded in Tissue-Tek OCT compound 
(Sakura Finetek Japan, Tokyo, Japan), and frozen on dry 
ice. Sections were cut at 12 μm for immunostaining.
To prepare paraffin sections, anesthetized mice 
were perfused intracardially with methacarn fixative 
(methanol:chloroform:acetic acid  =  6:3:1). Brains were 
removed, cut coronally, and post-fixed 2 h at 4 °C in the same 
fixative. For paraffin embedding, tissues were dehydrated in 
a graded series of alcohols, cleared with Hemo-De (a Xylene 
substitutive, FALMA, Tokyo, Japan), embedded in Paraplast 
Plus (Sigma, St. Louis, MO, USA), and sectioned at 4 μm.
To prepare unfixed, fresh frozen sections for immu-
nostaining, mice were killed by cervical dislocation and 
the brains were removed and frozen on dry ice. Sections 
were cut at 20 μm on a cryostat. To prepare paraffin sec-
tions for in  situ hybridization, the anesthetized mouse 
was perfused intracardially with PBS, followed by 4% PFA 
in PBS. Brains were removed and cut coronally, post-
fixed overnight (i.e. for at least 16 h), at 4  °C in 4% PFA 
in PBT (PBS containing 0.1% Tween 20). After rinsing in 
PBT, tissues were dehydrated in a graded series of etha-
nol in PBT, cleared with Hemo-De, embedded in Para-
plast Plus and sectioned at 5 μm.
Immunostaining for brain sections
For immunofluorescence staining of cryostat sections, 
sections were autoclaved in 10 mM citrate buffer, pH 6.0, 
for 5 min at 105 °C for antigen retrieval, and incubated in 
blocking solution (PBS containing 10% normal goat serum 
and 0.1% Triton X-100) for 1  h at room temperature 
(22–25  °C). The sections were then subsequently incu-
bated with primary antibodies overnight at 4 °C and with 
Alexa 488- or Alexa 594-conjugated secondary antibodies 
(Molecular Probes, Tokyo, Japan) for 1 h at room temper-
ature. Slides were mounted with Vectashield containing 
DAPI (Vector Laboratories, Burlingame, CA, USA).
Paraffin sections were deparaffinized with Hemo-De 
and rehydrated prior to staining. For immunohistochem-
istry, sections were further incubated in 0.3% H2O2/
methanol solution for 10  min to block the endogenous 
peroxidase activity. Sections were then incubated for 1 h 
at room temperature in blocking solution, which con-
sisted of 5% normal goat serum and 0.1% Triton X-100, 
followed by an overnight-incubation at 4 °C with primary 
antibodies diluted in blocking solution. Detection was 
performed with EnVision™ + Systems and DAB+, Liquid 
(Dako Japan, Tokyo, Japan). Sections were counterstained 
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with Mayer’s hematoxylin (Wako, Tokyo, Japan). Immu-
nofluorescence staining of the rehydrated sections was 
performed using the protocol outlined above for cryostat 
sections, but without the antigen retrieval. For immuno-
fluorescence staining of fresh frozen sections, sections 
was fixed in methanol (−20  °C, 30  min) and acetone 
(4  °C, 10  min), incubated with blocking buffer, primary, 
and fluorescently-labelled secondary antibodies. The 
following primary antibodies were used in this study: 
anti-GLUT9 (NBP1-05054, Novus Biologicals, 1/500 or 
1/1000 dilution for immunofluorescence staining, 1/5000 
dilution for immunohistochemistry); anti-acetylated-α-
tubulin (6-11B-1, Sigma, 1:500); anti-NeuN (A60, Mil-
lipore, 1/500); anti-P Glycoprotein (C219, GeneTax, 
1/200); anti-BCRP/ABCG2 (BXP-9, Abcam, 1/100). For 
antigen absorption experiment, GLUT9 peptide (NBP1-
05054PEP, Novus Biologicals) was used at a concentra-
tion of 100 μg/ml.
In situ hybridization
In situ hybridization was performed using ViewRNA™ 
ISH Tissue 2-Plex assay (Affymetrix, Tokyo, Japan) 
according to the manufacturer’s protocol. Paraffin sec-
tions were deparaffinized with Hemo-De, boiled in pre-
treatment solution for 10 min, and digested with protease 
for 10 min. Sections were then hybridized with ViewRNA 
probes (Mouse Slc22a12, Type 6; Mouse Slc2a9, Type 1: 
Mouse Abcg2, Type 1). Bound probes were amplified by 
hybridization with preamplifier and amplifier mix solu-
tions. Sections were incubated with Label Probe 6-alka-
line phosphatase (AP) solution and Fast Blue substrate. 
Subsequently, sections were incubated with Label Probe 
1-AP Type 1 solution and Fast Red substrate. Finally, the 
sections were counterstained with Gill’s hematoxylin and 
cover-slipped with Ultramount Permanent Mounting 
Medium (Dako Japan, Tokyo, Japan).
Image acquisition
DAB-stained sections were scanned with a NanoZoomer 
2.0-HT slide scanner (Hamamatsu Photonics, Hama-
matsu, Japan). For immunofluorescence experiments, 
single-plane images were captured using a Nikon A1 con-
focal microscope (Nikon, Tokyo, Japan) with identical 
settings. In  situ hybridization, fluorescence, and bright 
field images were also acquired with the Nikon A1 confo-
cal microscope. The Fast Blue and Fast Red signals were 
observed using Alexa 750 and Cy3 filter sets, respectively.
Results
Immunofluorescence staining of GLUT9 in PFA‑fixed 
murine brain sections
To determine whether GLUT9 is localized in ependy-
mal cells, we first performed immunostaining analysis 
using a rabbit polyclonal anti-GLUT9 antibody on PFA-
fixed murine brain frozen sections. Distinct GLUT9 
immunoreactivity in the ependymal cells of the dorsal 
third ventricle, and weaker staining in the brain paren-
chyma region were detected (Fig.  1a). The specificity of 
anti-GLUT9 antibody was verified by antigen absorp-
tion test (Fig. 1b). Higher magnification imaging revealed 
that GLUT9 was not localized to the nucleus or the cilia, 
visualized using anti-acetylated-α-tubulin, suggesting an 
intracellular and plasma membrane localization (Fig. 1c, 
d). To identify the cell type of GLUT9-positive cells in the 
brain parenchyma, we performed double immunostain-
ing for GLUT9 and NeuN (neuronal marker; Fig. 1e–g). 
All GLUT9-positive cells in the parenchyma co-localized 
with NeuN, suggesting that GLUT9 is also present in 
neurons.
GLUT9 immunoreactivity is detected in ependymal cells 
of all ventricles
Next, we observed the distribution of GLUT9 in other 
ventricles using PFA-fixed, frozen coronal sections at dif-
ferent levels. In addition to the ependymal cells of dorsal 
third ventricle (Figs. 1a, 2c), GLUT9 immunoreactivity was 
detected in ependymal cells of all ventricles including the 
lateral, ventral third, and fourth ventricles, and the aque-
duct (Fig. 2a, b, d–f). GLUT9 was also prominent in tany-
cytes, which are specialized ependymal cells that line the 
floor of the ventral third ventricle, and in its long processes 
that extend into the parenchyma (Fig.  2d). No immu-
nostaining was detected in the choroid plexus (Fig. 2b, c, f ).
Immunohistochemistry and immunofluorescence staining 
of GLUT9 in a methacarn‑fixed murine brain
Next, we performed immunostaining analysis using 
methacarn-fixed tissue. Similar to the results obtained 
from PFA-fixed tissue, GLUT9 immunoreactivity was 
detected in ependymal cells (Fig.  3a). In addition, cap-
illary-like structures were also immunopositive for 
GLUT9 in the brain parenchyma, including the cortical 
region (Fig. 3a, c). No staining was detected with antigen-
preabsorbed antibody (Fig.   3b). To investigate the dis-
tribution of GLUT9 in the brain capillary endothelium, 
we conducted double-immunostaining with anti-GLUT9 
and anti-P-glycoprotein (P-gp) antibody, which is a lumi-
nal marker (Fig.  3d–f). GLUT9 co-localized with P-gp 
(Fig. 3f ), indicating that GLUT9 possibly localizes to the 
luminal membrane of the brain capillary endothelium.
Immunofluorescence staining of ABCG2 in methanol/
acetone‑fixed and methacarn‑fixed murine brain
Immunohistochemistry of ABCG2 was done on fresh, 
frozen sections of the wild type (Fig. 4a) and Abcg2 KO 
(Fig. 4b) mice, which were post-fixed with methanol and 
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acetone. ABCG2 immunoreactivity on the luminal mem-
brane of the capillary endothelium and the CSF side of 
the choroid plexus epithelial cells has been previously 
reported [25]. Using a different antibody, we also demon-
strated a similar distribution of ABCG2 in the capillary 
endothelium and choroid plexus epithelial cells (Fig. 4a). 
These immunoreactivity patterns were not observed in 
sections from the Abcg2 KO mouse (Fig.  4b), demon-
strating antibody specificity. ABCG2 immunoreactivity 
was not detected in ependymal cells (Fig. 4c). Using par-
affin sections from methacarn-fixed brain, we observed 
the colocalization of ABCG2 and GLUT9 on the capillary 
endothelium (Fig. 4d–f).
Localization of mRNA of urate transporters in the murine 
brain by fluorescence in situ hybridization
The distribution of urate transporters in the murine 
brain was further verified by a highly-sensitive in  situ 
hybridization system using Slc22a12 (URAT1), Slc2a9 
(GLUT9), and Abcg2 probes. In accordance with our pre-
vious URAT1 immunostaining results, where URAT1 
was distributed in ependymal cells [13], Slc22a12 mRNA 
was expressed in the ependymal cells (Fig.  5a). Weaker 
signals were observed in choroid plexus and brain paren-
chyma where the protein localization was not confirmed 
(Fig. 5a). Slc2a9 mRNA was expressed broadly in epend-
ymal cells, the choroid plexus, and brain parenchyma 
(Fig. 5b). Abcg2 mRNA was expressed in choroid plexus 
epithelial cells and weakly in brain parenchyma, but not 
in ependymal cells (Fig.  5c). These results establish the 
validity of immunostaining results, which revealed the 
distribution of URAT1 and GLUT9 in ependymal cells, 
and of ABCG2 in the choroid plexus.
Discussion
In the current study, we showed that GLUT9 is expressed 
in ependymal cells, neurons, and brain capillaries, while 
ABCG2 is expressed in choroid plexus epithelium and 
brain capillaries, but not in ependymal cells. Taken 
together with our previous findings that URAT1 is local-
ized at the CSF side of the ependymal cells, we speculate 








Fig. 1 Immunofluorescence staining of GLUT9 in PFA-fixed murine brain sections. Frozen sections of paraformaldehyde-fixed wild-type murine 
brain were used for immunofluorescence staining. a, b Antigen absorption test. Immunofluorescence staining of the ependymal wall of the dorsal 
third ventricle using a anti-GLUT9 antibody and b antigen-preabsorbed antibody. Scale bar 100 µm. c, d Immunofluorescence staining of GLUT9 
(magenta), acetylated-tubulin (Ac-Tubulin, green) and DAPI (blue) on ependymal cells. Scale bar 10 µm. e–g Immunofluorescence staining of GLUT9 
(magenta) and NeuN (green) showing co-localization in neurons. Scale bar 10 µm. D3V, dorsal third ventricle; DAPI, 4′,6-diamidino-2-phenylindole; 
NeuN, neuronal nucleus marker
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at the cells which form the boundary between brain, CSF 
and blood.
While the immunoreactivity of GLUT9 in the ependy-
mal cells was consistently observed in our experiments, 
its immunoreactivity in neurons or brain capillaries was 
dependent on fixation or antigen retrieval conditions. 
The difference in the immunostaining pattern may be 
caused by antigen masking or degradation. The preser-
vation of antigenicity can be affected by fixation meth-
ods and may vary among tissues. Methacarn fixation 
is a non-cross-linking organic solvent, which has been 
shown to improve immunoreactivity, in comparison to 
aldehyde-based fixatives, against particular antigens 
[26]. The neuronal expression of GLUT9 is feasible, 
since its expression in cultured dopaminergic neurons 
has been previously demonstrated using western blot 
[23]. Two isoforms of GLUT9, which differ in the amino 
terminus, are known to exist in the human and mouse. 
The long isoform of human GLUT9 is expressed at the 
basolateral membrane of proximal tubules of human 
kidney, whereas the short isoform is expressed at the 
apical membrane of the collecting duct [21, 27]. In con-
trast, mouse GLUT9 is reportedly expressed both in 
the apical and basolateral membranes of distal convo-
luted tubules of the murine kidney and enterocytes of 
the murine jejunum, albeit with no information about 
its isoform-specific localization [22, 28, 29]. Since the 
current study did not reveal the exclusive plasma mem-
brane localization compared to our previous finding of 
apical localization of URAT1 [13], further work includ-
ing electron microscopy analysis is required to deter-
mine if GLUT9 is specifically localized in the apical 
and/or basolateral membrane of ependymal cells and 
neuronal somatic membranes. Unknown mechanisms, 
such as a stimulus-dependent translocation to the 
plasma membrane like the insulin-dependent GLUT4 
translocation may exist [30]. Surprisingly, we found 
that methacarn fixation alone showed the localiza-
tion of GLUT9 on brain capillary endothelial cells. This 
result supports RT-PCR findings that GLUT9 mRNA is 




Fig. 2 GLUT9/URATv1 immunoreactivity is detected in ependymal cells of all ventricles. Frozen sections of paraformaldehyde-fixed wild-type 
murine brain were used for immunofluorescence staining. The red squares in the diagrams indicate the region shown in each image. a–f GLUT9 
staining of coronal sections. b–d Images were obtained from the same section. Scale bar 100 µm. LV, lateral ventricle; V3V, ventral third ventricle; AQ, 
aqueduct; 4V, fourth ventricle
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The protein expression of URAT1 and GLUT9, but not 
ABCG2, in the ependymal cells was also validated by the 
use of highly-sensitive in  situ hybridization. Similarly, 
the expression of ABCG2 in choroid plexus cells was 
also confirmed. Slc2a9 and Abcg2 mRNA distribution 
in the brain parenchyma may correspond to the protein 
localization in neurons and brain capillary endothelial 
cells. Conversely, Slc22a12 mRNA signals were observed 
in the choroid plexus and the brain parenchyma, and 








Fig. 3 Immunohistochemistry and immunofluorescence staining of GLUT9 in methacarn-fixed murine brain. Paraffin sections of methacarn-fixed 
murine brain were used for immunostaining. a, b Antigen absorption test. Immunohistochemistry using showing a anti-GLUT9 antibody staining 
in the third ventricle ependyma and parenchyma and b antigen-preabsorbed antibody. Scale bar 100 µm. c GLUT9 immunoreactivity observed in 
brain capillaries in the cortex. Scale bar 100 µm. d–f Immunofluorescence staining of d GLUT9 and e P-gp showing co-localization in capillaries. Blue 









Fig. 4 Immunofluorescence staining of ABCG2 in methanol/acetone-fixed and methacarn-fixed murine brain. Fresh frozen sections of the dorsal 
third ventricle were prepared from wild-type (WT) and ABCG2 knockout (KO) mice and post-fixed with methanol and acetone. Immunofluo-
rescence staining of ABCG2 was seen in choroid plexus and capillaries in sections from a WT but not in b ABCG2 KO mouse. Scale bar 100 µm. c 
Immunofluorescence staining of ABCG2 (magenta) and GLUT9 (green) showing ABCG2 in the choroid plexus and GLUT9 in the ependyma. Scale bar 
100 µm. d–f Immunofluorescence staining of d ABCG2 and e GLUT9 using methacarn-fixed paraffin section of capillaries showing co-localization in 
f. Blue indicates DAPI-stained nucleus of the brain capillary endothelial cell. Scale bar 10 µm. CP, choroid plexus; D3V, dorsal third ventricle
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plexus, which is inconsistent with the immunostain-
ing results. Immunoblotting analysis in earlier studies 
has reported that URAT1 was detected in the murine 
choroid plexus, brain capillaries, cultured dopaminer-
gic neurons, and astrocytes [23, 33]. Our previous study 
exhibited weak immunostaining in the choroid plexus 
and the brain parenchyma, both in wild type and URAT1 
KO mice, indicating the possibility of non-specific stain-
ing [13]. The discrepancy between the immunostaining 
and in  situ hybridization data of GLUT9 (Slc2a9) and 
URAT1 (Slc22a12) could be considered that the mRNA 
is not translated to protein or that the translated protein 
is unstable. Alternatively, other optimum fixative condi-
tions for immunostaining may be needed.
Specific localization of UA transporters in the murine 
brain could be involved in the transport of UA derived 
from blood or by intracellular purine metabolism. Con-
sidering the correlation between blood and CSF UA levels 
[34], we suppose that brain interstitial UA could be mainly 
provided by CSF, which originates from blood at the cho-
roid plexus. The endothelial cells of the choroid plexus are 
fenestrated and tight junctions of choroid plexus epithe-
lial cells constitute the blood-CSF barrier [35]. Our group 
and others have demonstrated that ABCG2 is localized 
at the apical membrane of choroid plexus epithelial cells 
[25], raising the possibility that UA may be partly secreted 
by ABCG2 into the ventricular CSF. An unidentified UA 
transporter at the blood side may be involved in the uptake 
of blood UA into the choroid plexus epithelial cells. CSF 
flows through the ventricles, enters into the subarachnoid 
space, and is reabsorbed into the blood or reaches lym-
phatic drainage [36]. During the ventricular circulation, 
UA in the CSF could be transported into ependymal cells 
by URAT1 located at the apical membrane of ependymal 
cells [13]. Since it has been reported that ependymal cells 
express xanthine oxidase, which converts hypoxanthine to 
xanthine and xanthine to uric acid [37], metabolized UA 
in the ependymal cells could also be the transport target. 
If GLUT9 is localized at the basolateral membrane, then it 
is likely to contribute to the transport of UA from ependy-
mal cells to brain parenchyma. CSF-derived UA could 
increase the regional UA concentration near the ventricle, 
a b cSlc2a9Slc22a12 Abcg2
D3V
Fig. 5 Localization of mRNA of urate transporters in murine brain by fluorescence in situ hybridization. a–c Merged bright field and fluorescence 
images are seen in the upper panels, while the lower panels show the fluorescence images alone. Green dots show Fast Blue signal observed with the 
Alexa 750 filter set, while the red dots show Fast Red signal observed with the Cy3 filter set. mRNA probes: Slc22a12 (URAT1), Slc2a9 (GLUT9), Abcg2 
(ABCG2). Slc22a12 is expressed largely in the ependyma and less in the parenchyma, Slc2a9 is expressed in the ependyma and parenchyma and 
Abcg2 in the choroid plexus epithelium
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for example in the striatum near the lateral ventricles. 
Conversely, apically-localized GLUT9 could transport UA 
from ependymal cells to the ventricular CSF. It has been 
demonstrated that ATP-binding cassette transporters 
ABCG2 and MRP4/ABCC4 that transport UA are local-
ized to luminal membrane of endothelial cells [20, 25, 38]. 
At the abluminal membrane, OAT3, which can function 
as a urate/dicarboxylate exchanger, is present [39, 40]. In 
addition to these transporters, we revealed that GLUT9 
also exists at the capillary endothelial cells, albeit its lumi-
nal/abluminal distribution should be further investigated 
by electron microscopy analysis. We postulate that at the 
blood–brain barrier, UA in the capillary endothelial cell is 
excreted into blood via luminal ABCG2 and GLUT9 may 
also be involved in the UA transport at this site.
In the present paper, we have mainly discussed about 
the possible role of brain GLUT9 and ABCG2 regarding 
the transport activity of UA [41–43]. However, associa-
tion with other candidate substrates of the transporters 
needs to be taken into consideration. Initially, GLUT9 
was shown to be a high-affinity, low-capacity glucose 
and fructose transporter [44]. Other GLUT transport-
ers are also expressed in the brain [45] and among them, 
GLUT1 is highly expressed in both the luminal and ablu-
minal membranes of the endothelial cells and predomi-
nantly involved in the glucose transport into the brain 
[46, 47]. Whether the brain UA transporters are actually 
involved in the UA transport at the ependymal cells, cho-
roid plexus epithelial cells and brain capillary endothelial 
cells and the effect of competitive substrates should be 
ascertained in future studies including the direct meas-
urement of local UA at the cellular level.
It has recently been reported that genetic variants of 
SLC2A9 (GLUT9) and ABCG2, which influence the serum 
level of UA, can modify susceptibility to PD [3, 5, 6]. Fur-
ther, an elevated/reduced UA level in serum correlates 
closely with an elevated/reduced UA level in the brain [34]. 
Moreover, the dysfunction of regional UA transport in the 
brain may have additional effects on the level of UA in the 
brain. GLUT9 dysfunction in the ependymal cells may 
reduce the UA supply for brain parenchyma. ABCG2 dys-
function in the brain capillary endothelial cells may inhibit 
UA excretion into blood and maintain the brain paren-
chyma UA level. Since multiple UA transporters exist on 
the luminal side of endothelial cells, further investigation is 
required to reveal the main driver of UA transport.
Conclusions
In this study, we propose that UA in the brain could be 
transported by UA transporters, which show specific 
expression patterns in ependymal, choroid plexus epi-
thelial and brain capillary endothelial cells. Thus far, the 
importance of UA in the brain as an antioxidant has been 
widely discussed however, the dynamics of UA transport 
in the brain has remained unexplored. Further clarifica-
tion of the regulatory mechanism of the level of UA in 
the central nervous system would be helpful for the reali-
zation of targeted neuroprotective therapy.
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